drugset / Trial / NCT01822028

Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®

NCT01822028

Phase 1 Completed 42 enrolled Actelion
RandomizedCrossoverTriple-blindTreatment

Summary

Cross-over, tolerability study with healthy subjects taking Zavesca in combination with Florastor. Forty-two subjects will be randomized to one of two treatment sequences of Zavesca with Florastor and Zavesca with Placebo of Florastor. Gastrointestinal tolerability and PK endpoints, demographic, laboratory and safety testing, and AEs and SAEs will be collected throughout the seventy-four day study.

Timeline

Start
2013-03
Primary completion
2013-06
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Florastor® Unknown 500 mg
Subject Miglustat Small molecule 100 mg

Indications